Chen Yong, Li Wanwan, Zhou Jiangjiao, Wen Yu, Miao Xiongying, Xiong Li
Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014 Jan;39(1):102-8. doi: 10.11817/j.issn.1672-7347.2014.01.018.
Despite its more than 100-year history in experimental and clinical use, photodynamic therapy (PDT) is only starting to be appreciated for its full potential. PDT combines a photosensitizer and light in the presence of oxygen to treat cancer and other disorders. This paper reviews the molecular mechanism of PDT at the cellular level as well as in therapeutic settings in vivo. The availability of multiple photosensitizers with different structures and functional properties makes PDT an extremely versatile and, conversely, a challenging approach to cancer therapy. The advancing understanding of molecular pathways helps to design improved regimens. As most cancers are being treated with combined therapies, PDT is being integrated into rationally designed regimens that exploit molecular responses to PDT for improved efficacy.
尽管光动力疗法（PDT）在实验和临床应用已有100多年的历史，但人们才刚刚开始认识到其全部潜力。PDT在有氧存在的情况下将光敏剂和光结合起来治疗癌症和其他疾病。本文综述了PDT在细胞水平以及体内治疗环境中的分子机制。多种具有不同结构和功能特性的光敏剂的可用性使PDT成为一种极其通用的、反之也是具有挑战性的癌症治疗方法。对分子途径的深入理解有助于设计改进的治疗方案。由于大多数癌症采用联合疗法进行治疗，PDT正被纳入合理设计的治疗方案中，这些方案利用对PDT的分子反应来提高疗效。
